Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27855134 | 0.95 | POLB (0.44) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL29060151 | 0.95 | POLB (0.44) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL5992716 | 0.87 | ELANE (0.35) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL3055797 | 0.84 | CHRNB2 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL1441293 | 0.84 | CHRM2 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL17395379 | 0.84 | POLB (0.40) | POLBL3MBTL1NPC1RAB9AHRH3 | |
| SCHEMBL2463373 | 0.84 | POLB (0.40) | POLBL3MBTL1NPC1RAB9AHRH3 | |
| SCHEMBL1069972 | 0.83 | POLB (0.37) | CHRNB2CHRNA7CHRNA4POLBL3MBTL1 | |
| SCHEMBL11223074 | 0.83 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL17395471 | 0.82 | POLB (0.39) | POLBL3MBTL1NPC1RAB9AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1314728-A1 | Pyridyl and pyrimidinyl imines as intermediates for imidazole derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-28 | — | — | EP | claimed |
| EP-0831830-B1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | claimed |
| EP-0889888-A4 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORP (US) | 2003-01-08 | — | — | EP | claimed |
| US-20020123500-A1 | Use of CSAIDTM compounds as inhibitors of angiogenesis | SMITHKLINE BEECHAM CORPORATION | 2002-09-05 | — | — | US | claimed |
| US-6372741-B1 | ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2002-04-16 | — | — | US | claimed |
| EP-1021173-A1 | USE OF CSAID?TM COMPOUNDS FOR THE MANAGEMENT OF UTERINE CONTRACTIONS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2000-07-26 | — | — | EP | claimed |
| EP-1005343-A1 | USE OF CSAID?TM COMPOUNDS AS INHIBITORS OF ANGIOGENESIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-07 | — | — | EP | claimed |
| EP-1005343-A4 | USE OF CSAID?TM COMPOUNDS AS INHIBITORS OF ANGIOGENESIS | SMITHKLINE BEECHAM CORP (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1999018942-A1 | USE OF CSAIDTM COMPOUNDS FOR THE MANAGEMENT OF UTERINE CONTRACTIONS | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 1999-04-22 | — | — | WO | claimed |
| EP-0889888-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | claimed |
| EP-0831830-A4 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 1998-12-02 | — | — | EP | claimed |
| EP-0831830-A1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1997035856-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-02 | — | — | WO | claimed |
| WO-1997032583-A1 | USE OF CSAIDTM COMPOUNDS AS INHIBITORS OF ANGIOGENESIS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-12 | — | — | WO | claimed |
| US-5658903-A | Imidazole compounds, compositions and use | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-19 | — | — | US | claimed |
| WO-1996040143-A1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| US-6528512-B1 | Cytokine specific binding protein; | SMITHKLINE BEECHAM CORPORATION | 2003-03-04 | — | — | US | disclosed |
| US-20020123500-A1 | Use of CSAIDTM compounds as inhibitors of angiogenesis | SMITHKLINE BEECHAM CORPORATION | 2002-09-05 | — | — | US | disclosed |
| WO-1997032583-A1 | USE OF CSAIDTM COMPOUNDS AS INHIBITORS OF ANGIOGENESIS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-12 | — | — | WO | disclosed |
| US-4247694-A | PHOTOSTABILIZERS FOR POLYMERS | CIBA-GEIGY CORPORATION (US) | 1981-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123500-A1 | Use of CSAIDTM compounds as inhibitors of angiogenesis | VEGFA, IL1RN, CXCL12 | CHRNB2 4331/4885CHRNB4 4508/4885CHRNA3 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.